A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Trial Profile

A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Temsirolimus (Primary) ; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TOTEM
  • Most Recent Events

    • 07 Oct 2015 Accrual to date is 15% according to the United Kingdom Clinical Research Network record.
    • 12 Jun 2015 Accrual to date is 14% according to the United Kingdom Clinical Research Network record.
    • 23 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top